Dr. DeAnnuntis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4 George Bellows Way
Marlton, NJ 08053Phone+1 856-753-5153Fax+1 949-223-6995
Education & Training
- University of California (Irvine)Residency, Internal Medicine, 1993 - 1996
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1993
Certifications & Licensure
- NJ State Medical License 1997 - 2025
- PA State Medical License 1997 - 1998
Publications & Presentations
PubMed
- Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.Arun A Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi
European Journal of Cancer. 2024-12-01 - 10 citationsTalazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.Niven Mehra, Karim Fizazi, Johann S de Bono, Philippe Barthélémy, Tanya Dorff
The Oncologist. 2022-10-01 - 16 citationsPregnancy outcomes in patients treated with bosutinib.Jorge E. Cortes, Carlo Gambacorti-Passerini, Michael M.N. Deininger, Elisabetta Abruzzese, Liza DeAnnuntis
International Journal of Hematologic Oncology. 2020-05-29
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: